France
Argobio Studio, with its slogan "Turning cutting-edge innovations into breakthrough Biotech companies," represents a pioneering force in the Biotechnology industry. Established in 2021 and headquartered in France, this startup studio focuses on transforming early-stage innovations into successful biotech ventures.
The studio specializes in areas such as rare diseases, neurological disorders, oncology, and immunology, areas of significant unmet medical need. By sourcing novel therapeutics from prestigious European academic institutions, Argobio plays a crucial role in incubating and advancing these projects towards company formation. Their additional emphasis on developing platform technologies underlines their commitment to fostering a robust pipeline of therapeutic products.
Backed by leading investors, Kurma Partners, Bpifrance, Angelini Pharma, Evotec, and Institut Pasteur, Argobio was launched with a substantial €50.00M Series A investment in March 2021. This financial foundation positions Argobio Studio as a potent catalyst for innovation within the biotechnology sector.
